WG
RIGL icon

Winton Group’s Rigel Pharmaceuticals RIGL Stock Holding History

Winton Group’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,974
Closed -$513K – 1443
2026
Q1 		$513K Buy
18,974
+3,687
+24% +$124K 0.02% 705
2025
Q4 		$655K Buy
15,287
+4,198
+38% +$158K 0.02% 578
2025
Q3 		$314K Buy
+11,089
New +$332K 0.01% 623
2020
Q1 		– Sell
-5,262
Closed -$113K – 1518
2019
Q4 		$113K Buy
+5,262
New +$108K ﹤0.01% 1481

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Winton Group's RIGL Position: Q2 2026 in Review

Winton Group sold out of Rigel Pharmaceuticals (RIGL) in Q2 2026, closing a stake of 18,974 shares — an estimated $513K sold.

Winton Group first reported a position in RIGL in Q4 2019 and held it in 4 quarters. The position peaked at $655K in Q4 2025. 109 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Winton Group reported no remaining Rigel Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Winton Group sold 18,974 Rigel Pharmaceuticals shares in Q2 2026, an estimated $513K.
  • Winton Group first reported a position in Rigel Pharmaceuticals in Q4 2019 and held it in 4 quarters.
  • Winton Group's Rigel Pharmaceuticals position peaked at $655K in Q4 2025.
  • 109 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.